Although specific data on the relationship between AMPK activation and cisplatin (CDDP) resistance in sarcomas is lacking, existing evidence on AMPK activation in sarcomas (as presented in the first section of our review) and the positive outcomes of AMPK modulation to enhance CDDP response in other cancers suggest that AMPK modulation could be a promising strategy to improve treatment responses in sarcoma tumors [67]. This evidence concerns the gene PRKAA1 and cancer.